Endocrinology (all articles)
Cohort Study | Age at menopause and risk of heart failure and atrial fibrillation.
5 Aug, 2022 | 14:38h | UTCAge at menopause and risk of heart failure and atrial fibrillation: a nationwide cohort study – European Heart Journal (link to abstract – $ for full-text)
Editorial: Premature menopause and cardiovascular disease: can we blame estrogen? – European Heart Journal
News Release: Premature menopause is associated with increased risk of heart problems – European Society of Cardiology
Cohort study | Adults with Type 2 Diabetes and nonalcoholic fatty liver disease are at increased risk of severe hypoglycemia.
5 Aug, 2022 | 14:30h | UTCCommentary: Consider Fatty Liver Disease for Hypoglycemia Risk in Diabetes – JAMA Network Open (free registration required)
Commentary on Twitter
In this cohort study, participants with type 2 diabetes and nonalcoholic fatty liver disease without cirrhosis had a 26% increased risk of severe hypoglycemia diabetes independent of obesity status. https://t.co/Zh9tHkOmOa
— JAMA Network Open (@JAMANetworkOpen) February 23, 2022
In a cohort study with a median follow‐up of 23.2 years, both very low and very high LDL‐C levels are associated with increased risk of cardiovascular mortality in the general population.
4 Aug, 2022 | 14:25h | UTC
Cohort Study | Bariatric surgery linked to doubling chance of marriage or divorce.
4 Aug, 2022 | 14:16h | UTCNews Release: Bariatric Surgery Linked to Doubling Chance of Marriage or Divorce – University of Pittsburgh
Commentary: Spouse Getting Weight Loss Surgery? Your Marriage Might Be in Trouble – HealthDay
Network M-A | Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy.
4 Aug, 2022 | 13:30h | UTC
Commentary on Twitter
A new systematic review aimed to evaluate how different #ART regimens compare with respect to body #weight gains over time and associated risk factors.
Read here: https://t.co/MHC1Ysgb34 pic.twitter.com/0djjGPmlcW
— eClinicalMedicine – The Lancet Discovery Science (@eClinicalMed) May 24, 2022
Guideline | Preventing obesity in midlife women.
3 Aug, 2022 | 14:37h | UTCCommentary: Counseling Can Prevent Obesity in Normal, Overweight Women – HealthDay
Commentary on Twitter
New guidelines aim to prevent #obesity in midlife women. @TheWPSI recommends counseling to prevent weight gain in all women at normal or overweight BMI. Full text available at https://t.co/P8VwBWIHXe @CedarsSinai @acog pic.twitter.com/YxTQVgXj59
— Annals of Int Med (@AnnalsofIM) August 2, 2022
Study shows the incidence of obesity among US children is increasing.
3 Aug, 2022 | 14:00h | UTCChanges in the Incidence of Childhood Obesity – Pediatrics
Original Study: Childhood Obesity Rate in the U.S. Higher Now Than 12 Years Prior – HealthDay
M-A | GLP1 receptor agonists are associated with increased risk of progression of retinopathy in patients with type 2 diabetes.
2 Aug, 2022 | 12:32h | UTCProgression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes – A systematic review and meta-analysis – Journal of Diabetes and its Complications (link to abstract – $ for full-text)
Commentary: GLP1 RA use tied to increased risk of rapidly worsening retinopathy in type 2 diabetes – Medical Dialogues
RCT | Safety and efficacy of Tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan.
2 Aug, 2022 | 12:05h | UTCSafety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
See also (note: the dulaglutide dosage used in this trial was probably suboptimal): Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
Related:
Tirzepatide Once Weekly for the Treatment of Obesity – New England Journal of Medicine
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Online—Safety and efficacy of #tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 #diabetes in #Japan (#SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial https://t.co/r4v4QUsl5q #T2D pic.twitter.com/k6ihWy2vem
— The Lancet Diabetes & Endocrinology (@TheLancetEndo) July 31, 2022
RCT | Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity.
1 Aug, 2022 | 12:35h | UTCEndoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
MERIT trial suggests endoscopic sleeve gastroplasty should be considered as a synergistic weight loss intervention for patients with class 1 or class 2 obesity.
Find out more: https://t.co/FWeXeWbBF0 pic.twitter.com/W6qUKW92hR
— The Lancet (@TheLancet) July 30, 2022
Cohort Study | Long-term leisure-time physical activity intensity and all-cause and cause-specific mortality.
1 Aug, 2022 | 12:26h | UTCLong-Term Leisure-Time Physical Activity Intensity and All-Cause and Cause-Specific Mortality: A Prospective Cohort of US Adults – Circulation (free for a limited period)
News Release: New study finds lowest risk of death was among adults who exercised 150-600 minutes/week – American Heart Association
Perspective | Aspirin for the primary prevention of atherosclerotic cardiovascular disease in women.
1 Aug, 2022 | 12:25h | UTCAspirin for the Primary Prevention of Atherosclerotic Cardiovascular Disease in Women – JAMA (free for a limited period)
Cohort Study | Association of assisted reproductive technology with offspring growth and adiposity from infancy to early adulthood.
1 Aug, 2022 | 11:54h | UTC
Commentary on Twitter
This cohort study found that differences in early growth and adiposity for people conceived via assisted reproductive technology (vs. naturally) were small and reduced with older age. @aelhak19 @DeborahLawlor2 https://t.co/hwdldN6yDf
— JAMA Network Open (@JAMANetworkOpen) July 26, 2022
M-A | Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes.
29 Jul, 2022 | 12:37h | UTCCommentaries:
No justification for bespoke antihypertensive intervention in type 2 diabetes – medwire News
Blood pressure control according to type 2 diabetes status – The Lancet Diabetes & Endocrinology (free registration required)
Commentary on Twitter
Online—Blood pressure-lowering treatment for prevention of major #cardiovascular diseases in people with and without type 2 #diabetes: an individual participant-level data meta-analysis https://t.co/AmNxyW9Via #T2D #BloodPressure #hypertension #openaccess pic.twitter.com/NfdLktZXai
— The Lancet Diabetes & Endocrinology (@TheLancetEndo) July 25, 2022
Position Paper | Red yeast rice for dyslipidemias and cardiovascular risk reduction.
29 Jul, 2022 | 12:35h | UTC
RCT | Supplemental Vitamin D does not reduce incident fractures in midlife and older adults.
28 Jul, 2022 | 13:31h | UTCSupplemental Vitamin D and Incident Fractures in Midlife and Older Adults – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Daily Vitamin D supplements don’t lower risk of bone fractures, study finds – STAT
Related:
Commentary on Twitter
A study ancillary to a large trial showed that supplemental vitamin D3 did not lower the risk of fractures among generally healthy midlife and older adults not selected for vitamin D deficiency, low bone mass, or osteoporosis. https://t.co/vVTlizdffG pic.twitter.com/hQHJ7JizaV
— NEJM (@NEJM) July 27, 2022
Guideline | Management of diabetic macular edema.
28 Jul, 2022 | 13:18h | UTC
Consensus statement on the management of familial hypercholesterolemia.
28 Jul, 2022 | 13:16h | UTC
M-A | Effectiveness of wearable activity trackers to increase physical activity and improve health.
26 Jul, 2022 | 13:27h | UTC
Commentary on Twitter
Effectiveness of wearable activity trackers to increase physical activity and improve health: a systematic review of systematic reviews and meta-analyses https://t.co/JecWHjcnpg pic.twitter.com/MPnQHU1VQQ
— Søren T. Skou (@STSkou) July 21, 2022
Under a CC BY-NC-ND 4.0 license
RCT | Safety and efficacy of Liraglutide vs. Colesevelam for treating bile acid diarrhea.
26 Jul, 2022 | 12:29h | UTCSafety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary: Diabetes Drug for Bile Acid Diarrhea Bests Standard of Care in Small Trial — Liraglutide proves superior to colesevelam for cutting daily stool frequency in Danish trial – MedPage Today (free registration required)
Commentary on Twitter
New research – Kårhus et al – Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trialhttps://t.co/7Q69CcvjcJ#BAD #GITwitter @MKarhus @filip_Knop pic.twitter.com/lkfSLLgokO
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) July 20, 2022
RCT | Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus.
26 Jul, 2022 | 11:53h | UTC
M-A | TSH and FT4 reference intervals in pregnancy.
25 Jul, 2022 | 12:56h | UTC
Chasing LDL cholesterol to the bottom — PCSK9 in perspective.
22 Jul, 2022 | 11:36h | UTCChasing LDL cholesterol to the bottom — PCSK9 in perspective – Nature Cardiovascular Research (if the link is paywalled, try this one)
Commentary on Twitter
Review| @LaleTokgozoglu and Peter Libby discuss the management of #atherogenic #LDL cholesterol with an emphasis on the role #PCSK9 inhibition strategies https://t.co/k1wPKAdotU
— Nature Cardiovascular Research (@NatureCVR) June 17, 2022
An approach to the management of diabetes mellitus in cirrhosis: a primer for the hepatologist.
22 Jul, 2022 | 11:26h | UTC
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.
21 Jul, 2022 | 13:11h | UTC